Solid Biosciences Inc.

With apparently the first death of a patient dosed with its gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta incurred a significant reduction in its stock price on 18 March, as well as qu

Analysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US

BridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it

At least five biopharma companies have filed paperwork with the US Securities and Exchange Commission (SEC) since the start of 2024 to signal their intention to go public this year, entering what stil